EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Eli Lilly and Company announced on Wednesday, Dec. 27, that it has successfully completed its buyout of the radiopharmaceutical firm that develops cancer treatment, POINT Biopharma Global Inc. The deal is worth about $1.4 billion.
Total Shares Acquired
The multi-million price is for Eli Lilly's acquisition of almost 72.8 million shares of POINT Biopharma. This portion of the shares is said to correspond to more or less 67.97% of the outstanding shares.
As per RTT News, the biopharma firm has a line of clinical and preclinical-stage radioligand therapies that are currently in development. These are for the treatment of cancer diseases, and Eli Lilly is bound to benefit from this as the companies merge. In any case, with the acquisition, Point Biopharma is now set to be delisted from the Nasdaq.
Financial Terms and Other Details of the Deal
Eli Lilly's tender offer to buy all of the issued and outstanding shares of common stock of the Pittsburgh, Pennsylvania-headquartered biopharma company at a purchase price of $12.50 per share without interest has expired right on schedule of 5:00 p.m. on Dec. 22; thus an extension was not necessary. The amount will be paid in cash, less any applicable tax withholding.
"Next-generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this space through the addition of POINT," Loxo@Lilly's executive vice president and president, Jacob Van Naarden, said in a press release. "We welcome POINT colleagues to Lilly and look forward to working together to build on their work as we create this new capability within Lilly. In time, I hope we can bring several new radioligand therapies to patients with cancer and improve their outcomes."
Goldman Sachs & Co. LLC has been hired as Eli Lilly's exclusive financial advisor, while Kirkland & Ellis LLP is serving as its legal counsel. On the other hand, POINT Biopharma appointed Centerview Partners LLC as its financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP as its legal counsel.
Photo by: Lilly Press Release
